Intervention not reported
Ponesimod No direct evidence · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
It is very uncertain whether the intervention changes ponesimod No direct evidence (very low certainty).
1 finding from 1 review
OR 1.24 [0.66, 2.35]
Studies not reported
Very low
Intervention not reported
Teriflunomide (Direct evidence; 2 RCTs; 2253 participants) · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
It is very uncertain whether the intervention changes teriflunomide (Direct evidence; 2 RCTs; 2253 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Placebo · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Spasticity: number of participants reporting reduction of 30% in the spasticity NRS ( · health problem or population
Summary of findings table ‐ Cannabis probably leads to higher spasticity: number of participants reporting reduction of 30% in the… compared with placebo (moderate certainty).
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · health problem or population
It is very uncertain whether summary of findings table ‐ Cannabis changes pain:number of participants reporting pain relief of 50% or greater… compared with placebo (very low certainty).
1 finding from 1 review
Patient Global Impression of Change much or very much improved · health problem or population
Summary of findings table ‐ Cannabis probably leads to higher PGIC:number of participants reporting much or very much improvement… compared with placebo (moderate certainty).
1 finding from 1 review
Health‐related quality of life. Mean change from baseline · health problem or population
1 finding from 1 review
Number withdrawn due to adverse events · health problem or population
Summary of findings table ‐ Cannabis may leads to higher withdrawn due to adverse events ( compared with placebo (low certainty).
1 finding from 1 review
SAEs · health problem or population
Summary of findings table ‐ Cannabis showed no clear difference in SAEs: number of participants with SAEs ( compared with placebo (low certainty).
1 finding from 1 review
Specific adverse events:nervous system disorder · health problem or population
Summary of findings table ‐ Cannabis may leads to higher specific AEs:number of participants reporting nervous system… compared with placebo (low certainty).
1 finding from 1 review
Adverse events: psychological disorders · health problem or population
Summary of findings table ‐ Cannabis may leads to higher specific AEs: number of participants reporting psychiatric disorders ( compared with placebo (low certainty).
1 finding from 1 review
Specific AEs: number of participants reporting drug tolerance ( · health problem or population
It is very uncertain whether summary of findings table ‐ Cannabis changes specific AEs: number of participants reporting drug tolerance ( compared with placebo (very low certainty).
1 finding from 1 review
Stroke · preventing early recurrence after ischaemic stroke or TIA
Dual probably leads to lower stroke compared with one antiplatelet agent (moderate certainty).
1 finding from 1 review
Deaths due to vascular events · preventing early recurrence after ischaemic stroke or TIA
Dual showed no clear difference in vascular death compared with one antiplatelet agent (moderate certainty).
1 finding from 1 review
Myocardial infarction · preventing early recurrence after ischaemic stroke or TIA
Dual showed no clear difference in myocardial infarction compared with one antiplatelet agent (high certainty).
1 finding from 1 review
Stroke, myocardial infarction, or vascular death · preventing early recurrence after ischaemic stroke or TIA
Dual probably leads to lower stroke, myocardial infarction, or vascular death compared with one antiplatelet agent (moderate certainty).
1 finding from 1 review
Intracranial haemorrhage · preventing early recurrence after ischaemic stroke or TIA
Dual showed no clear difference in intracranial haemorrhage compared with one antiplatelet agent (low certainty).
1 finding from 1 review
Extracranial haemorrhage · preventing early recurrence after ischaemic stroke or TIA
Dual leads to higher extracranial haemorrhage compared with one antiplatelet agent (high certainty).
1 finding from 1 review
Ischaemic stroke · preventing early recurrence after ischaemic stroke or TIA
Dual leads to lower ischaemic stroke compared with one antiplatelet agent (high certainty).
1 finding from 1 review
Outcomes at ≥ 3 months · preventing early recurrence after ischaemic stroke or TIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found